To measure the long-term changes in weight, plasma lipids and fasting blood glucose after switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and in-patients with schizophrenia.
The measurement of weight and lipid profile and fasting blood glucose will be measured at baseline and every 3 months for 1 year.
